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Abstract: We developed a quality assurance (QA) tool, namely microarray outlier ﬁ  lter (MOF), and have applied it to our 
microarray datasets for the identiﬁ  cation of problematic arrays. Our approach is based on the comparison of the arrays us-
ing the correlation coefﬁ  cient and the number of outlier spots generated on each array to reveal outlier arrays. For a human 
universal reference (HUR) dataset, which is used as a technical control in our standard hybridization procedure, 3 outlier 
arrays were identiﬁ  ed out of 35 experiments. For a human blood dataset, 12 outlier arrays were identiﬁ  ed from 185 ex-
periments. In general, arrays from human blood samples displayed greater variation in their gene expression proﬁ  les than 
arrays from HUR samples. As a result, MOF identiﬁ  ed two distinct patterns in the occurrence of outlier arrays. These results 
demonstrate that this methodology is a valuable QA practice to identify questionable microarray data prior to downstream 
analysis. 
Introduction
Gene expression proﬁ  ling can help in identifying potential biomarkers to aid cancer classiﬁ  cation in 
addition to traditional pathology-based methods (Golub et al. 1999). For example, more than 200 genes 
have been shown to be highly associated with breast cancer and may be used to predict the clinical 
outcome of breast cancer (Hu et al. 2003; Paik et al. 2004). Recently, efforts have been made to identify 
serum biomarkers for the development of a blood-based gene expression test for the early detection of 
cancers (Sharma et al. 2005). Generation of high quality and reproducible data requires not only strict 
quality control (QC) of each experimental step, but also quality assurance (QA) that must be performed 
after laboratory experiments are complete. QA of raw data is essential because 1) it prevents low quality 
data from entering into later research analysis, and 2) it provides quick feedback for troubleshooting 
causes of the failed experiments. 
Microarray experiments are complicated processes involving multiple steps. From manufacturing 
of the arrays to data acquisition by scanning of hybridized arrays, numerous factors at any of these steps 
can lead to unwanted random or systematic variation in the data. The factors impacting microarray raw 
data can be technical, instrumental and computational (Shi et al. 2004). QA of microarray data is usually 
conducted at two levels: spot level and array level. To assess the quality at the individual spot level 
several methodologies have been proposed (Hautaniemi et al. 2003; Chen et al. 2002; Wang et al. 2001; 
Tran et al. 2002; Sauer et al. 2005). These algorithms usually assign a quality score to a spot based on 
properties or descriptors related to that spot. Unreliable data points are simply excluded from subsequent 
analysis. However, not all bad data points can be detected in this way. For example, the levels of decaying 
transcripts in the sample may be measured correctly but still reﬂ  ect artifacts. In such cases, it is neces-
sary to assess variation between arrays. To date, however, few publications are available on QA of 
microarray data at the array level. Traditionally, visual inspection of array images and scatter plots have 
been used to reveal problematic arrays. Burgoon et al. described an approach to compare arrays based 
on gross statistical features of datasets (Burgoon et al. 2005). Model et al. used PCA and multivariate 
statistics process control to detect outlier arrays (Model et al. 2002).
It is important to identify outlier arrays for microarray data analyses. The majority of statistical 
strategies for differential analysis of gene expression are derived from t-test or ANOVA based analyses 
(Amaratunga et al. 2004). A limitation to such approaches is that they depend upon accurate estimation 
of sample variance. However, the small sample sizes used in typical microarray experiments result in 
unreliable estimation of variance. The situation worsens in the presence of outlier arrays. Even with the Cancer Informatics 2006: 2 352
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introduction of statistical strategies such as Signif-
icance Analysis of Microarray (SAM) (Tusher et 
al. 2001) which was designed to correct unstable 
variance estimates, this problem of unreliable vari-
ance estimation is still only partially alleviated. In 
this paper, we tackle the problem by adopting 
objective QA criteria at the whole array level so 
that outlier arrays can be ﬂ  agged and treated differ-
ently in the downstream analysis. This approach 
will likely enhance the reliability of the differential 
gene expression analysis. In essence, our approach 




Blood Samples and RNA Extraction
The PAXgene blood RNA extraction system 
(PreAnalytiX, Hombrechtikon, Switzerland) was 
used to collect blood and extract RNA. The 
system consolidates and integrates the key steps 
of whole blood collection, nucleic acid stabiliza-
tion, and RNA puriﬁ  cation. It reduces the unpre-
dictability associated with RNA processing and 
provides enhanced accuracy of intracellular RNA 
analysis.
Blood samples were collected from donors 
enrolled in the Clinical Breast Care Project 
following IRB-approved protocols. 2.5 mls of 
blood were drawn by qualiﬁ  ed individuals directly 
into PAXgene tubes. The PAXgene tubes contain 
an additive that stabilizes cellular RNA and 
prepares the samples for RNA puriﬁ  cation. The 
samples were left in the PAXgene tubes overnight 
at room temperature and then stored at  –20°C or   
–80°C until use.
Next, tubes were removed from freezer and 
allowed to warm to room temperature overnight. 
Total RNA was extracted using the PAXgene blood 
RNA kit in accordance with the supplier’s instruc-
tions. The procedure started with a centrifugation 
step to pellet nucleic acids in the PAXgene tubes. 
The pellet was washed, resuspend, and incubated 
in optimized buffers containing Proteinase K to 
digest proteins. Residual cell debris was removed 
by centrifugation, and the resulting supernatant 
was transferred to a fresh microcentrifuge tube. 
Ethanol was added and mixed by vortexing. The 
lysate was then applied to a PAXgene RNA spin 
column and a brief centrifugation was used to 
remove contaminants while RNA was selectively 
bound to the silica-gel membrane of the column. 
Remaining contaminants were removed by three 
wash steps, and pure RNA was eluted using 
nuclease-free water. To denature the RNA, which 
was essential for maximum efﬁ  ciency in down-
stream applications including cDNA synthesis, 
the eluate was incubated brieﬂ  y at 65°C in a 
heating block. Following incubation, RNA 
samples were chilled immediately on ice. RNA 
concentration and purity was determined using a 
NanoDrop (Agilent, Foster City, CA) which 
provides absorbance measurements at 260nm and 
280nm. The A260/A280 ratio must be above 1.7 for 
use in microarray experiments. RNA quality was 
further checked using Agilent Bioanalyzer Nano 
Chip (Agilent, Foster City, CA). All extracted 
RNA must have a 28S/16S ratio greater than 1.5 
or a RNA Integrity Number (RIN) above 5 to pass 
this QA measure.
CodeLink Microarray and Hybridization
We used CodeLink Bioarrays (GE HealthCare, 
Piscataway, NJ) for microarray experiments. 
CodeLink utilizes a one-color labeling and detec-
tion method based on biotin-labeled cRNA. Human 
20K bioarray targets 19881 well-annotated human 
genes. Each transcript is represented by a 30-mer 
probe which is designed to conserve exons across 
the transcripts of targeted genes. Total RNA from 
each donor was linearly ampliﬁ  ed and hybridized 
to the CodeLink 20K human bioarray following 
the manufacturer’s recommended protocol. In 
brief, 1 μg of total RNA together with control 
bacterial mRNA was used to synthesize the ﬁ  rst 
strand cDNA by reverse-transcription, followed by 
the second strand cDNA synthesis. After puriﬁ  ca-
tion of these double-strand cDNA, in vitro tran-
scription was carried out to generate cRNA 
followed by biotin-labeling. An aliquot of these 
labeled cRNA was run on Agilent’s bioanalyzer 
for qualiﬁ  cation and quantization. A total of 10 μg 
of high quality cRNA was fragmented and then 
hybridized to CodeLink Bioarrays. If a sample did 
not yield enough cRNA or cRNA failed the quality 
control, the experiment would restart from cRNA 
ampliﬁ  cation from total RNA. After hybridization, 
arrays were washed, stained with Cy5 dye then 
scanned using ScanArray 5000 (Perkins Elmer, 
Wellesley, MA).Cancer Informatics 2006: 2 353
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Data Acquisition and Process
Scanned images were analyzed using CodeLink 
Expression software to generate raw data. We 
manually checked all the grids to be sure that no 
miss-griding occurred. Results were stored in a 
data warehouse internally developed for the inte-
gration of clinical, genomic and proteomic data. 
Perl was used to retrieve and preprocess data for 
the statistical analysis performed by R along with 
BioConductor. Spotﬁ  re (Spotﬁ  re, Inc., Somer-
ville, MA) was the visualization tool for the 
current study.
Experimental Datasets
Two groups of microarray datasets were used in 
this study: 35 arrays of a human universal refer-
ence (HUR) RNA sample (Stratagene, La Jolla, 
CA) and 185 arrays of human blood samples. An 
HUR sample was included in each microarray 
experiment as a control for systematic variation 
from experiment to experiment. These HUR 
experiments were carried out from September, 
2003 to December, 2004. This dataset was used 
to validate our QA methods and to gain a general 
assessment of the reproducibility of our experi-
ments. The human blood samples were composed 
of whole blood from 71 patients with benign 
breast lesions, whole blood from 82 patients with 
invasive breast cancer and whole blood from 30 
normal controls with no known breast disease. 
The human blood samples were subjected to 
microarray experimentation from July, 2003 to 
August, 2004. 
In this study, only a subset of the 20470 probes 
on a standard 20K array was used for QA analysis. 
Probes with median raw intensity across the array 
group (e.g. HUR or human blood samples) below 
200 or above 10000 were excluded. Based on our 
experience, we believe that intensity below the 
200 was too close to the background level; thus, 
the signal measurement might not be reliable. On 
the other hand, intensity above 10000 fell in the 
saturation range of the scanner and thus did not 
effectively reﬂ  ect the difference in the signal 
strength. Of the 7080 probes which satisﬁ  ed these 
criteria, only good data points, as judged by 
CodeLink spot quality measures, were included 
in our QA analysis. The selected datasets were 
then normalized by quantile normalization across 
the array group. All subsequent QA analyses were 
performed on the data preprocessed in this way.
Rationale and Algorithm
The CodeLink platform has rules to evaluate the 
quality of individual spot and to ﬂ  ag problematic 
data points. CodeLink also provides a QA measure, 
normalized threshold, to gauge the overall intensity 
of ﬂ  uorescent signal level on an array. A “too low” 
or “too high” signal level usually indicates system-
atic errors in the experiment, and results in rejec-
tion of the whole array. 
However, these QA measures only focus on a 
single array without considering its relationship 
with other arrays. We believe that it can be infor-
mative to view individual arrays as a whole against 
a group of arrays. By monitoring gross changes in 
a dataset of whole arrays, we expect to identify 
outlier arrays which are signiﬁ  cantly different from 
other arrays. Our approach is to compare statistics 
of an array to those of other arrays and look for 
arrays which are dissimilar to the majority of arrays 
in the whole group. These “unusual” arrays are 
candidates for failed arrays which will be investi-
gated further. It should be noted that this rationale 
is based on two assumptions. First, all samples for 
comparison are similar enough so that the expres-
sion levels of most genes are similar among the 
samples. When these samples are subjected to the 
same experimental protocol, it is expected that the 
gross expression proﬁ  les are the same for all the 
samples. Second, we are conﬁ  dent that most of our 
array data are of high quality thus consistent with 
each other. Therefore, a few “unusual” arrays stand 
out as suspected failed arrays. 
The HUR sample was obtained commercially. 
The manufacturer strived to reduce differences 
between samples from batch to batch. The 185 
human blood samples described in this paper were 
from different subjects. Although there were 
biological variations among these samples, based 
on our experience we expected that the variations 
were not large enough to substantially change the 
statistical features of the datasets. In addition, all 
samples were analyzed using the same experi-
mental protocol. Therefore, our samples were 
suited to the QA approach described above.
Two statistical indices were used for array 
comparison. The Pearson correlation coefﬁ  cient 
was computed for each and every pair of arrays in 
the analysis. A collection of the correlation coef-
ﬁ  cient values was arranged in a table (Table 2) to 
show similarity and consistency between arrays. 
An outlier array was expected to have low correla-
tion with other arrays. The other statistical index Cancer Informatics 2006: 2 354
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was the percentage of outlier data points on an 
array. Here an outlier data point was in the context 
of all data points of a speciﬁ  c probe across the array 
group. We used resistant z-score (Amaratunga 
et al. 2004, pp. 78) to identify an outlier. The 









where   X and  s are the median and MAD (median 
absolute deviation). As its name implies, a resistant 
z-score is resistant to outliers’ inﬂ  uences since the 
median and the MAD are used for calculation. It 
can tolerate up to 50% outliers without being 
distorted. A resistant z-score was computed for 
each data point. A data point with the absolute 
value of its resistant z-score larger than a preset 
threshold was designated as an outlier. In this study, 
we chose to set the threshold to 3 based on our 
experience with our datasets. We found that this 
threshold could distinguish outlier arrays from 
non-outlier arrays. We observed that the more an 
array differed from other arrays, the more outlier 
data points were detected on that array. Therefore, 
the percentage of outlier data points could be used 
as an indicator for an outlier array. This algorithm 
using correlation coefﬁ  cient and percentage of 
outlier spots was implemented as an R function: 
microarray outlier ﬁ  lter (MOF), which ranks the 
arrays by their possibility of failure based on these 
two statistical indices.
Visualization and Analysis 
in Spotﬁ  re
Correlation coefﬁ  cients were displayed in a corre-
lation table. All visualizations, including the heat 
map of the correlation table, the heat map showing 
the percentage of outliers, scatter plots between 
arrays, and images of spatial distribution of spots 
on arrays, were developed in Spotﬁ  re. Clustering 
of the correlation table was done by complete 
linkage hierarchical clustering using Euclidean 
distance as the similarity measure in Spotﬁ  re. To 
compare an array with a group of similar arrays in 
a scatter plot, a model array was constructed by 
taking the median of all intensity values of the same 
probe across all the arrays in that array group, as 
the value for that probe on the model array. Thus, 
the model array could be used to represent the 
group of arrays. To visualize the locations of probes 
on an array, a 2-D plot was constructed using local 
coordinates of the probes on the array as provided 
by CodeLink.
Results
Identiﬁ  cation of HUR Outlier Arrays
We applied our QA measures to the 35 HUR 
sample arrays which were expected to be highly 
consistent. The purpose of analyzing HUR data 
was to test and validate our QA measures. A 
correlation coefﬁ  cient was computed for each pair 
of the 35 arrays. The average correlation coefﬁ  -
cient for an array was used to assess the similarity 
of the array to other arrays. The percentage of 
outlier spots on each array was also calculated to 
serve as an additional indicator of “abnormal” 
arrays. Arrays with low correlation with the 
majority of other arrays and/or a higher percentage 
of outliers were suspected as outlier arrays. There 
were three arrays (T00225133, T00237520 and 
T00245878) which had substantially lower corre-
lation to other arrays. These three arrays also 
generated more outlier data points than other 
arrays (Table 1). The average correlation coefﬁ  -
cient among them was only 0.32. This fact was 
contradictory to the expectation that HUR arrays 
should perform consistently. Thus, these three 
arrays were ﬂ  agged as failed arrays. Later, we 
found that two of these arrays, T00225133 and 
T00245878, had been independently determined 
as failed arrays by the laboratory based on the 
median raw intensity—in fact these two arrays 
were arrays for testing purpose in the laboratory 
and we intentionally started this QA project with 
all the available arrays. T00225133 and T00245878 
gave median raw intensities of 800 and 25.5, 
respectively, while normal median raw intensity 
was expected to be around 100. According to the 
experimental protocol, these two arrays should 
be discarded. It was very encouraging that the 
results by our QA approach were conﬁ  rmed by 
independent laboratory measures. At the end our 
approach ﬂ  agged one previously unsuspected 
array as a failure.
Clustering of HUR Arrays
Correlation coefﬁ  cients of all array pairs were 
arranged into a correlation table (Table 2) which 
was visualized as a heat map in Spotﬁ  re. When the Cancer Informatics 2006: 2 355
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correlation table was rearranged by clustering the 
arrays, we observed that, excluding the three obvi-
ously bad arrays described above, the good arrays 
could be grouped into two main clusters (Figure 1). 
One cluster contained 11 arrays and the other 
contained 21 arrays. Arrays in the smaller cluster 
had lower average correlation and higher percentage 
of outlier spots than arrays in the larger cluster. In 
general, arrays with overall low correlation coef-
ﬁ  cient also contained more outlier points, indi-
cating that correlation coefﬁ  cient and percentage 
of outliers produced consistent results. This fact 
increased our conﬁ  dence in using the two statistical 
indices in our QA analysis.
We observed that arrays within a cluster typi-
cally had high correlation with each other while 
arrays between the two clusters displayed poor 
correlation (Fig. 1). In details, the average corre-
lation for arrays in the smaller cluster was 0.92, 
and that for the larger cluster was 0.93, whereas 
the average correlation of arrays between the two 
clusters was 0.83. These observations demon-
strated that while the clustering of the arrays into 
two groups was not an artifact, the difference 
between the two clusters was not large at all which 
was what one would expect when the experiments 
were performed with the same sample. Further 
study of the data using scatter plots showed that 
arrays within a cluster displayed tighter distribu-
tions than scatter plots of arrays between the 
clusters, and the latter contained some spots scat-
tering from one side of the diagonal direction 
(data not shown). Since the difference between 
the two clusters was not large, and the sizes of 
the two clusters were comparable, we did not 
think it was appropriate to eliminate one group 
as outlier arrays.
Spatial Bias of Data Points 
on HUR Outlier Arrays
Filtering out low-quality arrays helps prevent 
misleading results in the subsequent data analysis. 
At the same time, QA analysis can beneﬁ  t the 
laboratory by providing clues to possible causes 
to failed arrays. We set off to inspect the three 
outlier arrays more closely hoping to gain deeper 
insight into what might have gone wrong with these 
Table 1. Average correlation coefﬁ  cient and percentage of outlier points for the 35 HUR arrays.
Array  Av Cor  Otlr %  Array  Av Cor  Otlr %  Array  Av Cor  Otlr %
T00245878 0.3  42.23 T00209832 0.8  1.85 T00211006 0.84 0.37
T00237520 0.22 40.56 T00205609 0.78 1.71 T00216482 0.82 0.37
T00225133 0.49 28.21 T00211750 0.81 1.29 T00208091 0.84 0.27
T00208035 0.76 11.11 T00211760 0.81 1.16 T00208342 0.83 0.26
T00237506 0.78  5.32 T00210855 0.83 1.14 T00210907 0.84 0.23
T00208021 0.76  4.27 T00208020 0.8  1.03 T00208057 0.82 0.22
T00237505 0.78  4.16 T00216483 0.83 0.95 T00210996 0.83 0.19
T00237508 0.78  4.07 T00207911 0.83 0.91 T00210869 0.84 0.18
T00236213 0.79  3.7  T00209843 0.82 0.84 T00210856 0.83 0.16
T00245873 0.82  2.75 T00210891 0.83 0.72 T00207898 0.82 0.11
T00225122 0.79  2.63 T00208076 0.81 0.69 T00210880 0.83 0
T00209817 0.8  2.34 T00216489 0.83 0.68     
The average correlation coefﬁ  cient for each array is computed by averaging the correlation coefﬁ  cients of that array with every other 
array. Percentage of outlier spots on an array was computed by dividing the number of outlier spots by the total number of probes 
involved in the analysis. Data points with resistant z-score below  –3 or above 3 were counted as outlier spots.
Table 2. Correlation coefﬁ  cient table for selected HUR arrays.
Array B_0.00223_  B_0.00553_  B_0.00215_  B_1.00083_  B_1.00110_  B_0.00170_
B_0.00223_ 1.00  0.85  0.87  0.78  0.90  0.87
B_0.00553_ 0.85  1.00  0.86  0.93  0.83  0.83
B_0.00215_ 0.87  0.86  1.00  0.87  0.92  0.90
B_1.00083_ 0.78  0.93  0.87  1.00  0.81  0.83
B_1.00110_ 0.90  0.83  0.92  0.81  1.00  0.88
B_0.00170_ 0.87  0.83  0.90  0.83  0.88  1.00Cancer Informatics 2006: 2 356
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arrays by using scatter plots of signal intensity and 
a spatial distribution plot of the probes on the array 
(Fig. 2). In Figure 2A, the data points in the scatter 
plot of array T00237520 and the model array 
representing the 32 good arrays spread out loosely, 
demonstrating discrepancy between many data 
points on array T00237520 and the corresponding 
data points on the model array. When we displayed 
the locations of probes whose values on the model 
array were above 2000, an interesting spatial 
pattern appeared. Probes whose intensity values 
were comparable on both array T00237520 and the 
model array were concentrated in 4 blocks on the 
array (Fig. 2B). Probes with different intensity 
values on both arrays were mainly located in the 
remaining 12 blocks (Fig. 2C and D). Similarly, 
data points on array T00245878 matching corre-
sponding data points above 2000 on the model 
array were also found mostly in 6 blocks while 
inconsistent data points were mostly located in the 
other 6 blocks on array T00245878 (data not 
shown). No spatial bias of spot distribution was 
found for probes with intensity lower than 2000 
on the model array (data not shown). Therefore, at 
least part of the questionable data on arrays 
T00237520 and T00245878 could be attributed to 
problems in specific blocks within the array. 
Intriguingly, problematic blocks were not always 
the same blocks on these two failed arrays, 
suggesting the problem occurred more randomly 
than systematically. The scatter plot of array 
T00225133 and the model array took a different 
form than those between the model array and array 
T00237520 or array T00245878. We believe that 
there were other causes to the failure of array 
T00225133.
Identiﬁ  cation of Human Blood 
Outlier Arrays
The dataset of 185 human blood samples was 
analyzed the same way as the HUR sample arrays. 
Clustering OF HUR Slides
T00237 T00237508 T00225122 T00245873 T00208020 T00211760 T00210996 T00211006 T00210891
1 2 2 3 35
4.04 0
Figure 1. Clustering of the HUR arrays. The correlation coefﬁ  cient table for the 35 HUR arrays was clustered by hierarchical clustering and 
displayed as a heat map using Spotﬁ  re. From red color to green color, correlation coefﬁ  cient increases. The 3 outlier arrays were clustered 
in red.Cancer Informatics 2006: 2 357
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Figure 2. Biased spatial distribution of spots on array T00237520. (A) Scatter plot of log transformed intensity values with the x-axis for the 
values from this array and the y-axis for those from the model array. The highlighted spots (in black) were probes showing consistent and 
strong signals (intensity > 2000) in both arrays. (B) The physical locations of the probes on the array. Probes highlighted in (A) were more 
focused in 4 blocks (black dots). (C) Scatter plot similar to (A) but now the highlighted probes were those whose signal is strong on one 
array but weaker in the other. (D) Those probes of inconsistent performance were distributed mostly on the other 12 blocks.
It could be seen that some arrays had overall poor 
correlation with other arrays (Figure 3). The 
average correlation coefﬁ  cient for one array with 
the rest 184 was in the range of 0.69 to 0.91. 
Percentage of outlier points on the arrays spanned 
from 0.3% to 23.8%. The arrays were then sorted 
from most likely to least likely to be an outlier 
array according to either the average correlation 
coefﬁ  cient or the percentage of outlier points, 
respectively. Twelve arrays appeared in the top 30 
in both lists, and were designated as suspected 
failed arrays. Among them, four samples were from 
patients with benign breast lesions while eight 
samples were from patients with invasive breast 
cancer. So the outlier arrays were not a reﬂ  ection 
of the disease severity. We also investigated the 
association between the outlier arrays and the 
following factors: lots of arrays, lots of PAXgene 
tubes, dates of the experiments performed and 
individuals who performed the experiments. No 
apparent association was found.
Discussion
We performed QA analysis on two groups of micro-
array datasets. The HUR data was more homoge-
neous. It was used to test our QA approach 
employing correlation coefﬁ  cient and percentage of 
outlier spots as the QA measures. Having validated 
the QA approach, we performed the QA analysis in 
the same way on the dataset of 185 human blood 
samples and ﬂ  agged 12 arrays as candidates for 
failed arrays. We recommended that microarray 
experiments with these arrays be repeated. Further-
more, using images of spot distribution recon-
structed in Spotﬁ  re, we conﬁ  ned problematic areas 
in certain blocks on two failed arrays.
Although we demonstrated that our QA 
measures were effective in identifying low-quality 
arrays, it should be noted that it is important that 
the samples for the QA analysis are of similar 
expression proﬁ  le in general, and the experiments 
are conducted using the same protocol. Following 
these rules ensures that outlier arrays detected by 
our approach were not due to normal variation in 
expression proﬁ  le. For example, we checked corre-
lation between expression arrays done on samples 
from different mouse tissues and found that corre-
lation in array expression between the tissues was 
so low that clustering of the correlation table was 
strictly dictated by tissue type (data not shown). In 
such a scenario, a few highly similar outlier arrays 
were, instead of failed experiments, just normal 
expression proﬁ  les which differ from proﬁ  les of 
other samples. Such distinct categorization was not 
seen among the human blood samples, indicating 
variation among our samples was not large enough 
to invalidate this QA approach. We will not be 
surprised, however, that a solid human tissue may 
display a different expression proﬁ  le and thus is 
ﬂ  agged by our QA measures as different from 
human blood samples.
Essentially, our QA measures check consistency 
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that outlier arrays are always failed arrays. It is 
possible that the data from outlier arrays are good 
but other data are consistently wrong. One should 
always be cautious in rejecting outlier arrays as 
failed arrays. In our experiments involving the HUR 
sample, the outlier arrays were not consistent 
among themselves, making it impossible that all 
the outlier arrays were good. Therefore, we think 
that the outlier arrays were truly failed arrays. Based 
on our experience with the HUR sample, we have 
conﬁ  dence in the data quality of most of our human 
blood samples. Outlier arrays are likely caused by 
failed experiments although other causes can not 
be ruled out, e.g. the samples are biologically 
heterogeneous. It is still an open question whether 
the outlier arrays may represent some unusual 
samples, especially in the case of our human blood 
samples, the difference between the outlier arrays 
and the other arrays were not as dramatic as in the 
HUR arrays. More replicates of the outlier arrays 
should be done to address this issue.
Another issue in the application of our QA 
approach is how to set the threshold to reject an 
array. We do not think there is a universal standard. 
Even with the same data, correlation coefﬁ  cients 
can change with the number of probes involved in 
the QA analysis. Importantly, the thresholds for 
the average correlation coefficient and the 
percentage of outlier spots should be adjusted when 
arrays of unknown quality are analyzed. Thresh-
olds should be established empirically. Familiarity 
with historical data plays an important role in 
threshold decision-making. Our QA method is 

























Figure 3. Visualization of correlation between the 185 human blood samples (left panel) and percentage of outlier spots on each of these 
arrays (right panel). The correlation table of the human blood samples was displayed as a heat map with the red color representing low 
correlation and green color showing high correlation between a pair of arrays. The percentages of outlier spots for each array were also 
shown in a heat map on the right with the red and green color standing for high and low percentage of outlier spots, respectively. The arrays 
were in the same order from top to bottom in both heat maps and the subject categories were shown on the left side of the ﬁ  gure. Marked 
in dark green were 12 arrays that were ﬂ  agged as failed ones as described in the text.Cancer Informatics 2006: 2 359
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problems on an array. We inspect potential 
problems starting from the top of the lists of the 
potentially problematic arrays reported by MOF. 
Down the list we usually see the severity of prob-
lems decreasing. The setting of the threshold 
depends on the nature of samples, the goal of 
analysis and even the availability of resources, etc. 
Of the 35 HUR RNA experiments, 3 arrays signif-
icantly differed from the other arrays and were also 
different among themselves in regard to the average 
correlation coefﬁ  cient and percentage of outlier 
spots. In this case, it was logical to ﬁ  lter out only 
these three arrays as outlier arrays. However, with 
the 185 human blood samples, we did not see such 
a clear cut dividing of the arrays into outlier and 
normal arrays. Twelve arrays were flagged as 
problematic arrays not only because these arrays 
had relatively low correlation with other arrays and 
a high percentage of outlier spots but also because 
other techniques such as scatter plots and clustering 
provided additional evidence. It should be stressed 
that our QA approach just evaluates the likelihood 
of failure for each array. Not necessarily every 
batch of arrays must contain failed experiments. 
Two statistics are employed in our QA approach. 
With the HUR arrays, both statistics generated 
highly consistent results. With the human blood 
samples, there was overlap and discrepancy between 
outlier arrays screened separately by correlation 
coefﬁ  cient and percentage of outlier spots. Not 
every array which had poor correlation with the 
other arrays contained more outlier spots. This was 
not surprising because human blood samples were 
more heterogeneous than the HUR samples, and 
there were more human blood sample arrays than 
the HUR sample arrays in the current study. Intrin-
sically, the two statistics do not measure exactly the 
same properties of a dataset. It is natural they may 
give different results when the situation becomes 
complicated. Actually, it is an advantage that these 
two statistics can conﬁ  rm and compliment each 
other. Abnormal arrays detected by either one of 
the QA measures warrant further investigation. 
For the correlation coefﬁ  cient, a minimum of 
three arrays are needed to identify an outlier array 
mathematically. However, larger numbers of arrays 
can give more reliable results. Historical data can 
be used if insufﬁ  cient arrays are available. Even 
though the data may come from different projects, 
they can be pooled for this QA analysis as long as 
the two assumptions laid out in Rationale and 
Algorithm Section are satisﬁ  ed. 
Microarray technology has become more and 
more mature in the last several years. Technical 
replicates are rarely used, and biological replicates 
are counted on to reach a biological conclusion 
(Allison et al. 2006). However, microarray exper-
iments may still fail due to a variety of reasons 
including operating errors. Our approach evaluates 
microarray data quality based on the statistics of the 
whole array and ﬂ  ags arrays of low quality. It is 
not always necessary to discard the ﬂ  agged arrays 
since at times a substantial amount of good data 
points can still be salvaged by conducting analysis 
at the probe level (Hautaniemi et al. 2003; Sauer 
et al. 2005). It is also possible to make use of the data 
from arrays of low quality by down-weighting them 
in the whole data analysis (Ritchie et al. 2006). We 
expect that by combining our approach with other 
complementary approaches, a user can not only 
identify arrays of low quality, but also make the best 
use of the data generated from all the microarrays.
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